FDA Approves PANTOPRAZOLE SODIUM — Northstar Rx LLC

Northstar Rx LLC has received FDA approval for IV pantoprazole sodium (ANDA 215860), a significant move that promises to bolster the availability of a first-line injectable treatment for heartburn and gastroesophageal reflux disease. Competition in the intravenous mechanism market is expected to intensify, potentially driving down costs for hospital providers.